Behçet disease, familial Mediterranean fever and MEFV variations: More than just an association.

Autoinflammation Behçet disease Familial Mediterranean fever MEFV gene variants

Journal

Clinical immunology (Orlando, Fla.)
ISSN: 1521-7035
Titre abrégé: Clin Immunol
Pays: United States
ID NLM: 100883537

Informations de publication

Date de publication:
06 2023
Historique:
received: 13 04 2023
revised: 20 04 2023
accepted: 21 04 2023
medline: 24 5 2023
pubmed: 22 5 2023
entrez: 22 5 2023
Statut: ppublish

Résumé

Behçet disease (BD) and familial Mediterranean fever (FMF) are two inflammatory disorders that share many features including historical background, ethnical distribution and inflammatory characteristics. Several studies suggested that BD and FMF might occur in the same individual more commonly than expected. Additionally, the pathogenic MEFV gene variants, especially p.Met694Val, activating the inflammasome complex have been shown to increase the risk for BD in regions where both FMF and BD are prevalent. Whether these variants are associated with certain disease subtypes and whether they may help in the planning of treatment need to be explored. This review provides a recent overview of the plausible association between FMF and BD and the role of MEFV variants in the pathogenesis of BD.

Identifiants

pubmed: 37216220
pii: S1521-6616(23)00129-8
doi: 10.1016/j.clim.2023.109630
pii:
doi:

Substances chimiques

Pyrin 0
MEFV protein, human 0

Types de publication

Review Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

109630

Informations de copyright

Copyright © 2023. Published by Elsevier Inc.

Déclaration de conflit d'intérêts

Declaration of Competing Interest Emire Seyahi has received honoraria, consulting, or speaker fees from Novartis, Pfizer, and AbbVie. Serdal Ugurlu has received honoraria, consulting, or speaker fees from Novartis, Pfizer, Lilly and Celltrion. Shirkhan Amikishiyev has nothing to declare, Ahmet Gul has received honoraria, consulting, or speaker fees from Novartis, Pfizer, Lilly, AbbVie, R-Pharm.

Auteurs

Emire Seyahi (E)

Division of Rheumatology, Department of Internal Medicine, Istanbul University-Cerrahpasa, School of Medicine, Istanbul, Turkey. Electronic address: eseyahi@yahoo.com.

Serdal Ugurlu (S)

Division of Rheumatology, Department of Internal Medicine, Istanbul University-Cerrahpasa, School of Medicine, Istanbul, Turkey.

Shirkhan Amikishiyev (S)

Division of Rheumatology, Department of Internal Medicine, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey.

Ahmet Gul (A)

Division of Rheumatology, Department of Internal Medicine, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey. Electronic address: agul@istanbul.edu.tr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH